Apolipoprotein A-V Interaction with Members of the Low Density Lipoprotein Receptor Gene Family
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Apolipoprotein A-V is a potent modulator of plasma triacylglycerol levels. To investigate the molecular basis for this phenomenon we explored the ability of apolipoprotein A-V, in most experiments complexed to disks of dimyristoylphosphatidylcholine, to interact with two members of the low density lipoprotein receptor family, the low density lipoprotein receptor-related protein and the mosaic type-1 receptor, SorLA. Experiments using surface plasmon resonance showed specific binding of both free and lipid-bound apolipoprotein A-V to both receptors. The binding was calcium dependent and was inhibited by the receptor associated protein, a known ligand for members of the low density lipoprotein receptor family. Preincubation with heparin decreased the receptor binding of apolipoprotein A-V, indicating that overlap exists between the recognition sites for these receptors and for heparin. A double mutant, apolipoprotein A-V (Arg210Glu/Lys211Gln), showed decreased binding to heparin and decreased ability to bind the low density lipoprotein receptor-related protein. Association of apolipoprotein A-V with the low density lipoprotein receptor-related protein or SorLA resulted in enhanced binding of human chylomicrons to receptor-covered sensor chips. Our results indicate that apolipoprotein A-V may influence plasma lipid homeostasis by enhancing receptor-mediated endocytosis of triacylglycerol-rich lipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Rohlmann, A., Gotthardt, M., Hammer, R. E., & Herz, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1240 · Cited by 455
Kowal, R. C., Herz, J., Weisgraber, K. H., Mahley, R. W., Brown, M. S., & Goldstein, J. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)87014-4 · Cited by 445
Lai, C.-Q., Demissie, S., Cupples, L. A., Zhu, Y., Adiconis, X., Parnell, L. D., Corella, D., & Ordovas, J. M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400192-jlr200 · Cited by 163
Willems van Dijk, K., Rensen, P. C., Voshol, P. J., & Havekes, L. M. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00002 · Cited by 154
Interaction of the N-Terminal Domain of Apolipoprotein E4 with Heparin
Dong, J., Peters-Libeu, C. A., Weisgraber, K. H., Segelke, B. W., Rupp, B., Capila, I., Hernáiz, M. J., LeBrun, L. A., & Linhardt, R. J. (2001) · Biochemistry · doi:10.1021/bi002417n · Cited by 99
GLIEMANN, J., HERMEY, G., NYKJÆR, A., PETERSEN, C. M., JACOBSEN, C., & ANDREASEN, P. A. (2004) · Biochemical Journal · doi:10.1042/bj20040149 · Cited by 58
Self-citation
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501
Recent advances in physiological lipoprotein metabolism
Ramasamy, I. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0358 · Cited by 235
Nilsson, S. K., Christensen, S., Raarup, M. K., Ryan, R. O., Nielsen, M. S., & Olivecrona, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802721200 · Cited by 111
Self-citationRecent insights into factors affecting remnant lipoprotein uptake
Williams, K. J., & Chen, K. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328338cabc · Cited by 91
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons.
Gin, P., Yin, L., Davies, B. S. J., Weinstein, M. M., Ryan, R. O., Bensadoun, A., Fong, L. G., Young, S. G., & Beigneux, A. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802579200 · Cited by 85
Self-citationSorting receptor SORLA: cellular mechanisms and implications for disease
Schmidt, V., Subkhangulova, A., & Willnow, T. E. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2410-z · Cited by 65
Shu, X., Nelbach, L., Ryan, R. O., & Forte, T. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.004 · Cited by 54
Self-citationHuang, X., Zhao, S., Bai, L., Hu, M., Zhao, W., & Zhang, Q. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00350.x · Cited by 36
Apolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis
Trudy, M., Vineeta, S., & Robert, O. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150059 · Cited by 18
Ibi, D., Boot, M., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R., Rensen, P. C. N., Karpe, F., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100193 · Cited by 9
Metadata
- Authors
- Nilsson, S. K., Lookene, A., Beckstead, J. A., Gliemann, J., Ryan, R. O., & Olivecrona, G.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-02-28
- Volume
- 46
- Issue
- 12
- Pages
- 3896-3904
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2045974381
- Cited by
- 102
- References
- 8
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.